PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNotices
BuyersSuppliersNotices
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. Amgen Ltd
AM

Amgen Ltd

Cambridge
Large

Amgen Ltd is a biotechnology company that focuses on the development of innovative therapies in various therapeutic areas including cardiovascular, bone health, inflammation, and oncology. They are involved in research, development, and manufacturing of biopharmaceutical products.

amgen.com ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£1.4bn
Live
41
Buyers
8
12m
£853.9m
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities6
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts41 / 72
  • Top buyers8
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — Amgen LtdUpdated 13 Jul 2026

At a glance · for buyers and watchdogs

Amgen Ltd has won £1.4bn across 8 public-sector buyers, with 41 live contracts. No active Companies House risk flags.

Why: top buyer NHS England at 98% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
41 of 72Live contracts
98%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value

Commitments mapped to the Government Social Value Model themes.

⚑ Self-reported
—

No social-value commitments yet

Jobs, skills, environmental, inequality and community commitments appear here once a claimed supplier attributes them to awarded contracts, or once we detect them on the supplier’s website.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Sectors served · 1/8
Central government✓
Local government✓
NHS & health✓
Housing✓
Utilities & energy✓
Financial services✓
Education✓
Defence✓
Services · 3
Therapeutic AreasAmgen develops therapies in areas such as cardiovascular, bone health, inflammation, and oncology. ↗Clinical TrialsAmgen conducts clinical trials to evaluate the safety and efficacy of its products. ↗Research & DevelopmentAmgen has a robust research and development strategy focusing on human and disease biology, novel targets, and clinical trial optimization. ↗
Frameworks & DPS · 6 from notices
  • NHS National Framework Agreement for Adalimumab InjectionNHS England · £111.3m
  • NHS Framework Agreement for Trastuzumab InjectionNHS England · £56.7m
  • NHS Framework Agreement, Branded Medicines for London and South of EnglandNHS England · £13.3m
  • NHS England Framework Agreement - London - Tranche ANHS England · £10.6m
  • NHS Framework Agreement for Proprietary Pharmaceuticals - South of England (Tranche A)NHS England · £10.5m
  • NHS England - Midlands and East Branded Medicines - Tranche BNHS England · £9.2m

Extracted automatically from amgen.com on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships

Independently issued. Verification dates cross-checked against issuer registers.

↔ Cross-checked
—

No accreditations recorded

B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 41 live · 31 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
Ustekinumab
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)—01 Oct 2026£6.5m1.8 yrspending
Transitional Drugs 7
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)—01 Jul 2026£16.8m2 yrspending
NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026
NHS England—01 Sept 2026£813.9m2 yrspending
Transitional Drugs 6
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)—01 Mar 2026£1.6m2 yrspending
Project/Contract NHS National Framework for Denosumab Injection
NHS England—01 Jan 2026£15.1m12 mopending
NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025
NHS England3360000001 Sept 2025£47.0m2 yrsLive
NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National
NHS England3360000001 Sept 2025£9.4m2 yrsLive
NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024
NHS England3360000001 May 2024£11.2m4 yrsLive
NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024
NHS England3360000001 Mar 2024£17.6m2.5 yrsLive
NHS South of England Branded Medicines - Tranche A - September 2023
NHS England3360000001 Sept 2023£7.6m2 yrsClosed
Total live value £85.2m · mean award £19.0m1–10 of 72

Top buyers · 8 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England
45 contracts
98%
since 2017
2
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
4 contracts
2%
since 2026
3
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
11 contracts
0%
4
eTenderwales
1 contract
0%
5
Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts)
5 contracts
0%
6
The NHS Commissioning Board (operating under the name of NHS England)
4 contracts
0%
7
Northern Health and Social Care Trust NHSCT
1 contract
0%
8
BELFAST HEALTH AND SOCIAL CARE TRUST
1 contract
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire45 contracts
98%
Wales10 contracts
2%
Scotland11 contracts
0%
North West4 contracts
0%
Northern Ireland2 contracts
0%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). Amgen Ltd highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
AM
Amgen Ltd
No£853.9m—
DR
Dr Reddy's Laboratories (UK) Ltd
Yes£121.0m17
JA
Janssen-Cilag Ltd
Yes£117.6m16
AB
AbbVie Ltd
Yes£95.2m11
TA
Thornton and Ross Ltd
Yes£72.5m9
AC
ACCORD-UK LTD
Yes£71.2m18
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 31 Dec 2024
Confirmation statement
Up to date
Next due 14 Oct 2026
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
02354269
Status
Active
Type
Private limited
Incorporated
01 Mar 1989
Reg. office
216 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0WA
SIC codes
72110
Last accounts
31 Dec 2024
Next accounts due
30 Sept 2026

Directors & PSC

  • FLOROU, Paraskevi — director
    Appointed 20 Feb 2023
  • ABBERLEY, Russell James — director
    Appointed 01 Aug 2020
  • WALKER, Christopher Paul — director
    Appointed 15 Mar 2016
  • HODGES, Sophie Jane — secretary
    Appointed 22 Sept 2014
  • Amgen Inc. — person with significant control
    ownership of shares 75 to 100 percent · voting rights 75 to 100 percent · right to appoint and remove directors

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
AMGEN LIMITED
02354269 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.